Type 1 Diabetes
The Faustman Lab is currently conducting multiple clinical trials using Bacillus Calmette-Guérin (BCG), an inexpensive generic drug, as a treatment for type 1 diabetes. The BCG clinical trial program has been underway for over 10 years with hundreds of previous and current participants. A 150-patient, randomized, placebo-controlled, Phase II clinical trial is concluding later in 2023. We are eager to analyze and publish this data as soon as we can.
The study we are currently enrolling for is a randomized, placebo-controlled clinical trial in children with type I diabetes. This trial is actively recruiting 250 type I diabetic children aged 8-17. For more information on enrollment and to learn more, check out our brochures below and the advertisement on MGB Rally: https://rally.massgeneralbrigham.org/study/pedsbcgtrial.
If you would like yourself or your child to be considered for participation in our clinical trials, please fill out the Registration Form found at this link: https://redcap.link/faustmanimmunobiologylab. This will enter your information into our clinical trial registration system. We use this registration to screen and select patients for future studies. In addition, we will add you to our mailing list so that you can receive our newsletters and updates.